Surgical advances in bladder cancer: at what cost? (Q38424941)

3 September 2017

1 reference

title

Surgical advances in bladder cancer: at what cost? (English)

1 reference

3 September 2017

1 reference

David C Johnson

1

1 reference

3 September 2017

Peter S Greene

series ordinal

2

1 reference

3 September 2017

Matthew E Nielsen

series ordinal

3

1 reference

3 September 2017

publication date

3 March 2015

1 reference

Urologic Clinics of North America

3 September 2017

published in

1 reference

3 September 2017

volume

42

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

235-52, ix

1 reference

Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

The health economics of bladder cancer: a comprehensive review of the published literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

The health economics of bladder cancer: an updated review of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Clinical model of lifetime cost of treating bladder cancer and associated complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Estimates and projections of value of life lost from cancer deaths in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Improving bladder cancer patient care: a pharmacoeconomic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Economic aspects of bladder cancer: what are the benefits and costs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

National trends in the utilization of robotic-assisted radical cystectomy: an analysis using the Nationwide Inpatient Sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Systematic review and meta-analysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Robotic vs. open radical cystectomy in bladder cancer: A systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Robotic or open radical cystectomy, which is safer? A systematic review and meta-analysis of comparative studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Robot-assisted laparoscopic vs open radical cystectomy: comparison of complications and perioperative oncological outcomes in 200 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Comparison of early postoperative morbidity after robot-assisted and open radical cystectomy: results of a prospective observational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

EAU guidelines on robotic and single-site surgery in urology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

A randomized trial of robot-assisted laparoscopic radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Long-term outcomes of robot-assisted radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Current status of robotic assisted pelvic surgery and future developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

When should quality of life be measured after radical cystectomy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Short-term patient-reported quality of life after robot-assisted radical cystectomy using the Convalescence and Recovery Evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Short-term patient reported health-related quality of life (HRQL) outcomes after robot-assisted radical cystectomy (RARC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Mu-opioid antagonists for opioid-induced bowel dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Implementation of the Exeter enhanced recovery programme for patients undergoing radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Economic analysis of alvimopan in North American Phase III efficacy trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Economic analysis of alvimopan for prevention and management of postoperative ileus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

7 January 2021

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

Cost-effectiveness of open versus laparoscopic versus robotic-assisted laparoscopic cystectomy and urinary diversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.005

10.1016/J.UCL.2015.01.005

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference